Summary of Study ST002251

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001439. The data can be accessed directly via it's Project DOI: 10.21228/M8QD9Z This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002251
Study TitleUntargeted metabolomics on plasma from children with asthma, comparing exacerbation-prone to non-exacerbation-prone
Study TypeUntargeted MS
Study SummaryBackground: Some children with asthma remain poorly controlled and have recurrent exacerbations despite treatment with inhaled corticosteroids. Aside from prior exacerbations, there are currently no reliable predictors of exacerbation-prone asthma in these children and limited understanding of potential underlying mechanisms. Objective: We sought to quantify small molecules in the plasma of children with exacerbation- prone asthma through mass spectrometry-based metabolomics. We hypothesized that the plasma metabolome of these children would differ from that of children with non-exacerbation- prone asthma. Methods: Plasma metabolites were extracted from four pediatric asthma cohorts (n=215 total, n=41 with exacerbation-prone asthma) and detected using a ZIC-HILIC column coupled to a Q Exactive HF mass spectrometer. High-confidence annotations were retained for univariate analysis and were confirmed by a sensitivity analysis in subjects on high-dose inhaled corticosteroids. Metabolites that varied by cohort were excluded. Metaboanalyst was used to identify pathways of interest. Concentrations were calculated by reference standardization to NIST SRM 1950. Results: We identified 32 unique, cohort-independent metabolites that differed in children with exacerbation-prone asthma compared to children with non-exacerbation-prone asthma. Comparison of metabolite concentrations to literature-reported values for healthy children revealed that most metabolites were decreased in both asthma groups, but more so in exacerbation-prone asthma. Pathway analysis identified arginine, lysine, and methionine pathways as most impacted. Conclusions: Several plasma metabolites are perturbed in children with exacerbation-prone asthma and are largely related to arginine, lysine, and methionine pathways. While validation is needed, plasma metabolites may be potential biomarkers for exacerbation-prone asthma in children.
Emory University
LaboratoryJoshua Chandler, PhD
Last NameChandler
First NameJoshua
Address2015 Upper Gate Drive NE, Atlanta, GA 30322
Submit Date2022-07-25
Num Groups2
Total Subjects215
Num Males135
Num Females80
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2023-01-02
Release Version1
Joshua Chandler Joshua Chandler application/zip

Select appropriate tab below to view additional metadata details:


Subject ID:SU002337
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Age Or Age Range:6-17 years
Weight Or Weight Range:Non-exacerbation-prone IQR: 30-68 kg; Exacerbation-prone IQR: 42-63 kg
Height Or Height Range:Non-exacerbation-prone IQR: 131-165 cm; Exacerbation-prone IQR: 140-163 cm
Gender:Male and female
Human Race:18 white, 189 Black, 7 more than one race, 1 Asian
Human Ethnicity:2 Hispanic, 113 Not Hispanic
Human Medications:92 on high-dose inhaled corticosteroids; 94 on long-acting beta adrenergic receptor agonists; 111 on Montelukast
Human Smoking Status:24 exposed to tobacco smoke
Human Inclusion Criteria:1) current or historical evidence of >=12% reversibility in forced expiratory volume in one second (FEV1) relative to baseline after bronchodilator administration; 2) airway hyperresponsiveness to methacholine, with a provocative concentration of methacholine causing a 20% drop in FEV1
Human Exclusion Criteria:1) premature birth before 35 weeks of gestation; 2) other chronic airway disorders that could mimic asthma.